Cover Image
市場調查報告書

Cathepsin B (APPsekuretaze/Cathepsin B1/EC 3.4.22.1):開發平台分析

Cathepsin B (APP Secretase or Cathepsin B1 or CTSB or EC 3.4.22.1) - Pipeline Review, H2 2017

出版商 Global Markets Direct 商品編碼 363573
出版日期 內容資訊 英文 34 Pages
訂單完成後即時交付
價格
Back to Top
Cathepsin B (APPsekuretaze/Cathepsin B1/EC 3.4.22.1):開發平台分析 Cathepsin B (APP Secretase or Cathepsin B1 or CTSB or EC 3.4.22.1) - Pipeline Review, H2 2017
出版日期: 2017年09月30日 內容資訊: 英文 34 Pages
簡介

所謂Cathepsin B (CatB) ,是屬於肽酶的酵素蛋白質之一,為了結合肽以寬廣特異性促進蛋白質的水解。切割在小分子基材中-Arg-Arg-Xaa-的結合。作為內肽酶,並表示二肽酶活動,打開C端肽。

本報告提供Cathepsin B (APPsekuretaze/Cathepsin B1/EC 3.4.22.1的)開發平台的現狀及最新更新的各開發階段比較分析,企業和研究機關開發中的治療藥,治療藥的評估,後期階段及中止的計劃相關資訊等最新的新聞和發表。

簡介

  • 調查範圍

Cathepsin B (APPsekuretaze/Cathepsin B1/EC 3.4.22.1) :概要

治療藥的開發

  • 開發中的產品:各開發階段
  • 開發中的產品:各治療領域
  • 開發中的產品:各症狀

開發中產品概況

  • 初期階段的產品

企業開發中的產品

大學/研究機關開發中的產品

治療藥的評估

  • 單劑/並用治療藥的情況
  • 各作用機制
  • 各給藥途徑
  • 各分子類型

治療藥開發作的企業

  • ALSP, Inc.
  • BioMAS Ltd.
  • Oncomatryx Biopharma, S.L.
  • Phelix Therapeutics, LLC
  • Virobay Inc.

藥物簡介

暫停中的計劃

主要消息及新聞稿

附錄

圖表

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GMDHC1032TDB

Summary

Cathepsin B (APP Secretase or Cathepsin B1 or CTSB or EC 3.4.22.1) - Cathepsin B (CatB) is an enzymatic protein belonging to the peptidase. It promotes hydrolysis of proteins with broad specificity for peptide bonds. It cleaves -Arg-Arg-|-Xaa bonds in small molecule substrates. In addition to being an endopeptidase, shows peptidyl-dipeptidase activity, liberating C-terminal dipeptides.

Cathepsin B (APP Secretase or Cathepsin B1 or CTSB or EC 3.4.22.1) pipeline Target constitutes close to 9 molecules. Out of which approximately 6 molecules are developed by companies and remaining by the universities/institutes. The molecules developed by companies in Phase I, Phase 0, Preclinical and Discovery stages are 1, 1, 3 and 1 respectively. Similarly, the universities portfolio in Preclinical and Discovery stages comprises 2 and 1 molecules, respectively. Report covers products from therapy areas Central Nervous System, Oncology, Gastrointestinal, Immunology and Infectious Disease which include indications Alzheimer's Disease, Liver Fibrosis, Autoimmune Disorders, Breast Cancer, Cancer Pain, Ebolavirus Infections (Ebola Hemorrhagic Fever), Neuropathic Pain, Non-Alcoholic Steatohepatitis (NASH), Pancreatic Cancer, Primary Biliary Cirrhosis and Traumatic Brain Injury.

The latest report Cathepsin B (APP Secretase or Cathepsin B1 or CTSB or EC 3.4.22.1) - Pipeline Review, H2 2017, outlays comprehensive information on the Cathepsin B (APP Secretase or Cathepsin B1 or CTSB or EC 3.4.22.1) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews key players involved in Cathepsin B (APP Secretase or Cathepsin B1 or CTSB or EC 3.4.22.1) targeted therapeutics development with respective active and dormant or discontinued projects.

The report is built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

  • The report provides a snapshot of the global therapeutic landscape for Cathepsin B (APP Secretase or Cathepsin B1 or CTSB or EC 3.4.22.1)
  • The report reviews Cathepsin B (APP Secretase or Cathepsin B1 or CTSB or EC 3.4.22.1) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved in Cathepsin B (APP Secretase or Cathepsin B1 or CTSB or EC 3.4.22.1) targeted therapeutics and enlists all their major and minor projects
  • The report assesses Cathepsin B (APP Secretase or Cathepsin B1 or CTSB or EC 3.4.22.1) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report summarizes all the dormant and discontinued pipeline projects
  • The report reviews latest news and deals related to Cathepsin B (APP Secretase or Cathepsin B1 or CTSB or EC 3.4.22.1) targeted therapeutics

Reasons to buy

  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand the targeted therapy areas and indications for Cathepsin B (APP Secretase or Cathepsin B1 or CTSB or EC 3.4.22.1)
  • Identify the use of drugs for target identification and drug repurposing
  • Identify potential new clients or partners in the target demographic
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding Cathepsin B (APP Secretase or Cathepsin B1 or CTSB or EC 3.4.22.1) development landscape
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Introduction
    • Global Markets Direct Report Coverage
  • Cathepsin B (APP Secretase or Cathepsin B1 or CTSB or EC 3.4.22.1) - Overview
    • Cathepsin B (APP Secretase or Cathepsin B1 or CTSB or EC 3.4.22.1) - Therapeutics Development
    • Products under Development by Stage of Development
    • Products under Development by Therapy Area
    • Products under Development by Indication
    • Products under Development by Companies
    • Products under Development by Universities/Institutes
  • Cathepsin B (APP Secretase or Cathepsin B1 or CTSB or EC 3.4.22.1) - Therapeutics Assessment
    • Assessment by Mechanism of Action
    • Assessment by Route of Administration
    • Assessment by Molecule Type
  • Cathepsin B (APP Secretase or Cathepsin B1 or CTSB or EC 3.4.22.1) - Companies Involved in Therapeutics Development
    • ALSP Inc
    • Oncomatryx Biopharma SL
    • Phelix Therapeutics LLC
    • Virobay Inc
  • Cathepsin B (APP Secretase or Cathepsin B1 or CTSB or EC 3.4.22.1) - Drug Profiles
    • ALP-496 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • CIBP-4 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Drugs to Inhibit Cathepsin B for Ebola Viral Infections - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • OMTX-001 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Small Molecule to Inhibit Cathepsin B for Oncology - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Small Molecules to Inhibit Cathepsin B for Alzheimer's Disease - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • VBY-285 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • VBY-376 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • VBY-825 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
  • Cathepsin B (APP Secretase or Cathepsin B1 or CTSB or EC 3.4.22.1) - Dormant Products
  • Cathepsin B (APP Secretase or Cathepsin B1 or CTSB or EC 3.4.22.1) - Product Development Milestones
    • Featured News & Press Releases
      • Apr 19, 2016: American Life Science Pharmaceuticals Obtains Patent
      • Jan 25, 2016: ALSP invited to Give Oral Presentation at the Keystone TBI Conference January 25-27 in Santa Fe, New Mexico
      • Nov 14, 2011: Virobay's Spectrum-Selective Cathepsin Inhibitor Shows Efficacy In Bone Cancer Model
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
  • Disclaimer

List of Tables

  • Number of Products under Development by Stage of Development, H2 2017
  • Number of Products under Development by Therapy Areas, H2 2017
  • Number of Products under Development by Indication, H2 2017
  • Number of Products under Development by Companies, H2 2017
  • Products under Development by Companies, H2 2017
  • Number of Products under Investigation by Universities/Institutes, H2 2017
  • Products under Investigation by Universities/Institutes, H2 2017
  • Number of Products by Stage and Mechanism of Actions, H2 2017
  • Number of Products by Stage and Route of Administration, H2 2017
  • Number of Products by Stage and Molecule Type, H2 2017
  • Pipeline by ALSP Inc, H2 2017
  • Pipeline by Oncomatryx Biopharma SL, H2 2017
  • Pipeline by Phelix Therapeutics LLC, H2 2017
  • Pipeline by Virobay Inc, H2 2017
  • Dormant Projects, H2 2017

List of Figures

  • Number of Products under Development by Stage of Development, H2 2017
  • Number of Products under Development by Therapy Areas, H2 2017
  • Number of Products under Development by Top 10 Indications, H2 2017
  • Number of Products by Stage and Mechanism of Actions, H2 2017
  • Number of Products by Stage and Route of Administration, H2 2017
  • Number of Products by Molecule Types, H2 2017
  • Number of Products by Stage and Molecule Types, H2 2017
Back to Top